Larvol Delta - HiSQOL-outcomes-are-rapidly-improved-with-sonelokimab-in-the-Phase-3-VELA1-and-VELA2-trials-HSspecific-qualityoflife-scores-in-patients-with-moderatetosevere-HS

sonelokimab (M1095) - Avillion, MoonLake Immunotherap

https://pagv3.virtual-meeting.org/eadv/eadvcongress2026/en-GB/pag/presentation/63474

John R. Ingram

Aug 6, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next